The treatment of chronic inflammatory diseases and cancer is on the cusp of a revolution related to the recent advances in biotechnology. Classical treatments by chemical drugs have shown their limits but some new drugs obtained from the patient itself are starting to emerge. These advanced therapy medicinal products (ATMPs) have an exceptional application potential, but require to rethink the production process of these drugs from living materials. Their manufacture requires implementing complex technology in a controlled environment. This work is part of the MIMEDI project (Microtechnology for advanced therapy medicinal products) which involves 10 partners (6 companies, 3 academic partners and a transfer agency).

More information : Phd_position_Mimedi_Femto-ST.pdf